查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2002832

2型糖尿病治疗市场：2026-2032年全球市场预测（依药物类别、给药途径、治疗线、品牌类型、病患年龄层、病患性别及分销管道划分）

Type 2 Diabetes Drugs Market by Drug Class, Route Of Administration, Treatment Line, Brand Type, Patient Age Group, Patient Gender, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2 型糖尿病药物市场在 2025 年的价值为 17.6 亿美元，在 2026 年增长到 18.9 亿美元，到 2032 年达到 29.1 亿美元，复合年增长率为 7.41%。

主要市场统计数据
基准年 2025 17.6亿美元
预计年份：2026年 18.9亿美元
预测年份：2032年 29.1亿美元
复合年增长率 (%) 7.41%

对现代 2 型糖尿病治疗格局进行简明策略概述，将临床创新、交付模式和商业性。

2型糖尿病仍然是临床上最复杂、商业性最具活力的治疗领域之一。快速的治疗创新与不断演变的护理模式和支付方的期望相互交织。本执行摘要整合了影响产品开发、临床定位和商业性执行的核心趋势，涵盖药理分类、给药途径、治疗线、分销管道和患者群体。本文檔旨在帮助企业主管将临床进展和监管趋势转化为可执行的策略重点。

新的治疗进展和综合护理服务的创新正在重塑糖尿病护理的临床重点，并重新调整驱动商业性决策的因素。

2型糖尿病的治疗格局正经历一系列相互促进、同步发生的变革，这些变革共同改变了商业性和临床决策的方向。肠促胰素和钠-葡萄糖共同输送体（SGLT）生物学的突破性进展提升了多系统获益药物的重要性，促使临床医生和保险公司从更广泛的心肾代谢角度评估治疗方法。因此，药物的选择决策不仅越来越受到即时血糖值指标的影响，也越来越受到真实世界疗效以及长期发病率和死亡率数据的影响。

我们评估进口关税变化方案如何改变整个糖尿病治疗价值链的供应韧性、采购经济性和策略采购决策。

预计2025年关税调整和贸易政策转变将进一步增加製药企业、经销商和医疗保健系统的营运复杂性。活性成分、製剂或给药装置的进口关税增加可能会改变接收成本，并影响生产地点选择、库存缓衝和供应商合约等方面的决策。如果关税造成持续的成本差异，企业可能会加快近岸外包和双重采购策略，以维持供应的连续性和利润率。

将药物类别、给药途径、治疗方案、分销管道、品牌类型和患者人口统计与策略挑战联繫起来的综合細項分析。

精细的细分揭示了每个治疗领域、剂型、治疗定位、分销管道、品牌地位和患者群体的不同机会和风险。在药物类别中，双胍类药物保持着基础性地位，其製剂差异（例如组合药物、缓释製剂和速释製剂）会影响耐受性和依从性。 DPP-4抑制剂根据特定的分子实体进行区分，例如阿格列汀、Linagliptin、沙格列汀和sitagliptin，每种药物都具有独特的安全性和相互作用特征，从而影响医生的选择。 GLP-1受体促效剂在药物方面表现出显着的异质性，例如Dulaglutide、Exenatide、Liraglutide和Semaglutide，其给药频率、减重效应和心血管信号传导会影响治疗方法选择。胰岛素製剂分为基础型、餐后型及混合型。基础型胰岛素抑制剂包括德谷胰岛素、地特胰岛素和甘精胰岛素；餐后型抑制剂包括Aspart、Glulisine和Lispro；混合抑制剂有 50/50、70/30 和 75/25 三种剂型。每种亚组都会影响剂量调整的复杂性和给药装置的兼容性。 SGLT2 抑制剂包括Canagliflozin、DapagliflozinEmpagliflozin和艾格列净等药物，每种药物都有其独特的心血管和肾臟结局数据，这些数据决定了保险公司对其的定价。磺酰尿素类和胰岛素增敏剂酮类药物包括氯磺Glimepiride、格列美脲、Glipizide、吡格PIOGLITAZONE和Rosiglitazone等成分，它们继续发挥重要作用，尤其是在某些临床情况下，成本和已确定的耐受性是主要考虑因素。

严格的监管、支付方结构以及医疗保健基础设施的区域差异，导致世界主要地区获得糖尿病治疗的管道各不相同。

区域趋势影响监管时间表、支付方行为和病患就医途径，进而对临床应用和商业性实施产生重大影响。在美洲，监管和支付体系的特点是快速采纳已证实具有心肾和代谢获益的实证治疗方法。私人和公共保险公司之间的复杂互动也影响处方药清单和用药管理。该地区还拥有成熟的专科药物分销管道和先进的数位医疗技术，这可能会加速患者接受注射疗法和远距医疗剂量调整方案。

为了在糖尿病治疗中创造临床价值并维持治疗生命週期，企业策略集中在证据生成、伙伴关係和生产韧性。

领先的製药和生技公司正积极应对不断变化的糖尿病治疗格局，采取广泛的策略性倡议，包括专注于投资GLP-1和SGLT2生物学、扩大胰岛素生产能力，以及建立整合药品、医疗设备和数位化互动领域的伙伴关係。许多机构正优先考虑血糖控制终点以外的证据生成，投资于心血管和肾臟结局研究、真实世界数据（REW）项目和卫生经济学建模，以支持与支付方进行基于价值的合约谈判。在公司层面，生命週期管理策略强调在新剂型、给药装置和扩展适应症方面的创新，以维持临床意义并延长产品寿命。

经营团队利用可操作的策略挑战来加速以患者为中心的治疗实施，同时协调证据产生、供应弹性和支付方参与。

产业领导者应采取多管齐下的策略，将临床差异化、供应可靠性和支付方参与度结合，以维持药物可及性和商业性绩效。首先，应优先产生可靠的真实世界数据和疗效数据，将治疗方法与心血管和肾臟事件的减少联繫起来。这将显着加强与支付方和综合医疗保健系统的对话。其次，应实现筹资策略多元化，并加快区域性生产模式的开发，以降低关税和供应链风险，同时保持获利柔软性和病患可及性。第三，应投资于创新给药平台，例如缓释製剂和易于使用的注射器，并将其与能够提高用药依从性和改善健康结果的数位化用药依从性解决方案相结合。

调查方法结合了对关键相关人员的访谈、对二手证据的严格整合以及稳健的检验，以确保可操作的见解和分析的严谨性。

本执行摘要的分析整合了多项定性和定量研究，以确保提供可靠且可操作的见解。主要研究包括对临床医生、支付方代表、药房负责人和行业高管的深入访谈，以了解关于药物相容性行为、报销决定因素和供应链限制等方面的实际观点。次要研究包括对同行评审的临床实验室报告、监管申报文件、已裁定的结果研究和指南更新进行系统性回顾，以检验治疗定位和安全性讯号。

为了指导糖尿病治疗整个生命週期中的策略决策，需要采用结合临床创新、支付方趋势和营运弹性的综合方法。

整体而言，目前第2型糖尿病的临床创新加速发展，支付方期望不断变化，营运压力日益增大，所有这些都要求采取综合性的策略应对措施。具有多重器官获益的治疗方法，尤其是那些对心血管和肾臟系统有益的疗法，正在重塑临床模式；同时，给药方式和数位化支持的创新也在重新定义药物依从性和治疗的连续性。此外，不断变化的贸易政策和供应链的脆弱性也要求采取积极主动的采购和生产策略，以维持药物的可及性和市场竞争。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：第2型糖尿病治疗市场：依药物类别划分

  • 双胍类药物
    • 组合药物
    • 缓释製剂
    • 快速起效配方
  • DPP-4抑制剂
    • 阿格列汀
    • Linagliptin
    • 沙格列汀
    • sitagliptin
  • GLP-1受体促效剂
    • Dulaglutide
    • Exenatide
    • Liraglutide
    • Semaglutide
  • 胰岛素
    • 基础
      • 德格鲁德克
      • 德特米尔
      • 格拉金
    • 饭后
      • Aspart
      • Glulisine
      • Lispro
    • 预混合料
      • 50/50混合物
      • 70/30 混合
      • 75/25 混合
  • SGLT2抑制剂
    • Canagliflozin
    • Dapagliflozin
    • Empagliflozin
    • 艾格列净
  • 磺酰尿素类药物
    • 氯丙酰胺
    • Glimepiride
    • Glipizide
    • 格里布赖德
  • 胰岛素增敏剂药物
    • PIOGLITAZONE
    • Rosiglitazone

第九章：第2型糖尿病治疗药物市场：依给药途径划分

  • 注射药物
    • 笔型
    • 预填充式注射器
  • 口服
    • 胶囊
    • 药片

第十章：第2型糖尿病药物市场：依治疗方案划分

  • 第 1 行
    • 联合治疗
      • 双重联合治疗
      • 三联联合治疗
    • 单药治疗
  • 第二行
  • 第三行

第十一章：第2型糖尿病治疗药物市场：依品牌类型划分

  • 品牌
  • 非专利的

第十二章：第2型糖尿病治疗市场：依患者年龄组别划分

  • 18-65岁
  • 65岁或以上

第十三章：第2型糖尿病药物市场：病人性别

  • 女士
  • 男性

第十四章：第2型糖尿病治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十五章：第2型糖尿病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：第2型糖尿病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章：第2型糖尿病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国第二型糖尿病治疗市场

第十九章：中国第2型糖尿病治疗药物市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Chong Kun Dang Pharmaceutical Corp.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Hanmi Pharmaceutical Co., Ltd.
  • Innovent Biologics Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-7162E4C3E9C3

The Type 2 Diabetes Drugs Market was valued at USD 1.76 billion in 2025 and is projected to grow to USD 1.89 billion in 2026, with a CAGR of 7.41%, reaching USD 2.91 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.76 billion
Estimated Year [2026] USD 1.89 billion
Forecast Year [2032] USD 2.91 billion
CAGR (%) 7.41%

Concise strategic overview of the contemporary type 2 diabetes therapeutic environment linking clinical innovation, delivery models, and commercial priorities for leadership

Type 2 diabetes remains among the most clinically complex and commercially dynamic therapeutic areas, with rapid therapeutic innovation intersecting with evolving care models and payer expectations. This executive summary synthesizes core trends shaping product development, clinical positioning, and commercial execution across pharmacological classes, routes of administration, treatment lines, distribution channels, and patient demographics. It is structured to help senior leaders translate clinical progress and regulatory developments into pragmatic strategic priorities.

Across treatment modalities, the landscape is being reshaped by agents that extend beyond glycemic control to address cardiovascular, renal, and weight-related outcomes. At the same time, digitization of care pathways, patient-centric adherence solutions, and evolving reimbursement frameworks are redefining how therapies are adopted and utilized. Stakeholders must balance innovation with access considerations to sustain long-term patient benefit while preserving commercial viability. The following sections unpack transformative shifts, regulatory and trade-related headwinds, segmentation-level insights, regional nuances, corporate strategies, and tactical recommendations to guide leadership decision-making. Each section integrates current clinical and commercial intelligence and highlights implications for portfolio management, supply chain strategy, and stakeholder engagement.

Emerging therapeutic advances and integrated care delivery innovations are reshaping clinical priorities and reshuffling commercial decision levers in diabetes care

The therapeutic landscape for type 2 diabetes is experiencing a set of concurrent, reinforcing shifts that collectively reorient commercial and clinical decision-making. Breakthroughs in incretin and sodium-glucose cotransporter biology have elevated agents with multi-system benefits, prompting clinicians and payers to assess therapies through a broader cardiorenal-metabolic lens. As a consequence, formulary decisions are increasingly influenced by real-world outcomes and long-term morbidity and mortality data rather than immediate glycemic metrics alone.

Simultaneously, the rapid acceptance of long-acting injectable and novel oral formulations has expanded patient choice, necessitating nuanced positioning strategies that align administration mode with adherence patterns and patient preference. Digital therapeutics and remote monitoring are moving from pilot projects toward integrated disease-management solutions, enabling longitudinal adherence support and more granular value demonstration to payers. Parallel to these clinical and technological shifts, competitive dynamics are being reshaped by lifecycle management, biosimilar emergence, and cross-sector partnerships that combine pharmaceutical expertise with devices, diagnostics, and software. Together, these forces are accelerating demand for differentiated evidence generation, adaptive pricing strategies, and targeted provider engagement to realize both clinical benefit and commercial success.

Assessing how evolving import tariff scenarios could alter supply resilience, procurement economics, and strategic sourcing decisions across the diabetes therapeutic value chain

Potential tariff changes and trade policy shifts in 2025 introduce an added dimension of operational complexity for pharmaceutical manufacturers, distributors, and health systems. Increased import duties on active pharmaceutical ingredients, finished formulations, or delivery devices can alter landed costs and influence decisions about production geography, inventory buffers, and supplier contracts. Where tariffs create persistent cost differentials, firms are likely to accelerate nearshoring and dual-sourcing strategies to preserve continuity of supply and margin integrity.

Beyond unit cost implications, tariff-driven supply chain adjustments can elongate lead times and raise the operational premium on quality control and regulatory harmonization across jurisdictions. Payers and integrated delivery networks may respond to higher procurement costs by intensifying formulary management, seeking therapeutic substitutions where clinically appropriate, or renegotiating procurement contracts with manufacturers. For manufacturers, this environment increases the importance of transparent cost-of-goods analysis, scenario planning, and proactive engagement with payers to articulate value propositions tied to long-term health outcomes.

Finally, tariff pressures can intensify collaboration between pharmaceutical companies and contract manufacturers to localize critical production steps, while also amplifying investments in manufacturing efficiency and biologics capacity. For product teams, understanding the interplay between trade policy, supply resilience, and pricing dynamics will be essential for preserving patient access and sustaining lifecycle strategies in the coming years.

Comprehensive segmentation analysis linking drug classes, administration routes, treatment lines, distribution channels, brand typologies, and patient demographics to strategic imperatives

Granular segmentation reveals differentiated opportunities and risks across therapeutic classes, modes of delivery, treatment positioning, channels of distribution, brand status, and patient demographics. Within drug classes, biguanides maintain a foundational role with formulation-level differentiation across combination formulations, extended release, and immediate release options that affect tolerability and adherence profiles. DPP-4 inhibitors differentiate by specific molecular entities such as alogliptin, linagliptin, saxagliptin, and sitagliptin, each presenting distinct safety and interaction profiles that inform prescriber preference. GLP-1 receptor agonists show pronounced heterogeneity driven by agents such as dulaglutide, exenatide, liraglutide, and semaglutide, where dosing frequency, weight-loss effects, and cardiovascular signals influence therapeutic selection. Insulin products are stratified into basal, prandial, and premixed categories, with basal options like degludec, detemir, and glargine, prandial options like aspart, glulisine, and lispro, and premixed formulations spanning 50/50, 70/30, and 75/25 mixes; each subgroup has implications for titration complexity and delivery device compatibility. SGLT2 inhibitors comprise agents such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, each with distinct cardiovascular and renal outcome data that shape payer positioning. Sulfonylureas and thiazolidinediones, with constituents like chlorpropamide, glimepiride, glipizide, glyburide, pioglitazone, and rosiglitazone, remain relevant in specific clinical contexts, especially where cost and established tolerability profiles are primary considerations.

Route of administration segmentation distinguishes injectable formats, including pen and prefilled syringe devices, from oral capsules and tablets, and this division materially affects adherence, patient education needs, and device-related supply chain considerations. Treatment line segmentation-first line, second line, and third line-requires careful mapping of combination versus monotherapy strategies, where first-line combination approaches further bifurcate into dual and triple therapy regimens, each presenting unique evidence generation and payer negotiation requirements. Distribution channel dynamics across hospital pharmacy, online pharmacy, and retail pharmacy influence stocking practices, cold chain obligations, and point-of-care education, while brand type segmentation between branded and generic products drives differential pricing, promotion, and lifecycle tactics. Patient demographics such as age cohorts (18 to 65 and above 65) and gender differences (female and male) call for tailored adherence programs, comorbidity-aware treatment selection, and communications calibrated to differing risk profiles and healthcare utilization patterns. Integrating these segmentation layers enables more precise targeting of clinical development, commercial deployment, and outcomes measurement across the full product lifecycle.

Regional variations in regulatory rigor, payer mechanisms, and healthcare infrastructure shape differentiated adoption pathways for diabetes therapies across major global regions

Regional dynamics influence regulatory timelines, payer behavior, and patient access in ways that materially affect clinical adoption and commercial execution. In the Americas, regulatory and payer ecosystems are characterized by rapid uptake of high-evidence therapies that demonstrate cardiorenal-metabolic benefits, alongside a complex interplay between private insurers and public payers that shapes formulary positioning and utilization management. This region also features mature specialty distribution channels and advanced digital health adoption, which can accelerate patient onboarding to injectable therapies and remote titration programs.

The Europe, Middle East & Africa region presents pronounced heterogeneity; western European markets often prioritize robust health economic evidence and health-technology assessments when evaluating new therapies, requiring rich real-world data and cost-effectiveness analyses. Middle Eastern markets frequently focus on expedited access and volume-based procurement models, while African markets face infrastructure constraints and affordability barriers that influence therapy selection and distribution strategies. Navigating this regional mosaic requires tailored regulatory engagement plans and adaptable commercial models that respect local procurement mechanisms and reimbursement pathways.

Asia-Pacific exhibits diverse therapeutic trajectories, with some markets adopting novel agents rapidly due to growing cardiometabolic disease burden and strong primary care networks, while others emphasize local manufacturing and generic substitution to manage costs. In several countries, government-driven initiatives to strengthen diabetes screening and chronic disease management are expanding care pathways, creating opportunities for integrated therapeutic and digital solutions. Across all regions, regional supply chain optimization, evidence localization, and culturally sensitive patient support programs are critical to converting clinical innovation into sustainable patient access.

Corporate strategies converge on evidence generation, partnerships, and manufacturing resilience to capture clinical value and sustain therapeutic lifecycles in diabetes care

Leading pharmaceutical and biotech companies demonstrate a spectrum of strategic responses to the evolving diabetes landscape, including focused investments in GLP-1 and SGLT2 biology, expansion of insulin manufacturing capacity, and partnerships that integrate drug, device, and digital engagement. Many organizations are prioritizing evidence generation beyond glycemic endpoints by investing in cardiovascular and renal outcomes studies, real-world evidence programs, and health-economic modeling to support value-based contracting discussions with payers. At the corporate level, lifecycle management strategies emphasize new formulations, delivery device innovation, and indication expansion to sustain clinical relevance and extend product longevity.

Strategic alliances between established manufacturers and emerging biotech firms are accelerating the translation of novel mechanisms and combination approaches into clinical development. Contract manufacturing and specialized API partnerships are being used to mitigate capacity constraints and diversify supply bases. Companies are also investing in omnichannel commercial models that combine provider education, digital patient support, and targeted field force engagement to improve persistence and adherence. Finally, corporate strategies are increasingly incorporating sustainability and manufacturing resilience objectives to address environmental, social, and governance expectations while reducing operational risk.

Actionable strategic imperatives for leadership to align evidence generation, supply resilience, and payer engagement while accelerating patient-centric adoption of therapies

Industry leaders should adopt a multi-pronged approach that aligns clinical differentiation, supply reliability, and payer engagement to sustain access and commercial performance. First, prioritize generation of robust real-world evidence and outcomes data that link therapies to reductions in cardiovascular and renal events, as this will materially strengthen conversations with payers and integrated health systems. Second, diversify sourcing strategies and accelerate regional manufacturing options to mitigate tariff and supply-chain risk while preserving margin flexibility and patient access. Third, invest in delivery-platform innovation, including long-acting formulations and user-friendly injection devices, paired with digital adherence solutions that demonstrate improvements in persistence and health outcomes.

Additionally, pursue value-based contracting pilots with performance-based reimbursement linked to meaningful clinical endpoints, and tailor these agreements to regional payer expectations and regulatory realities. Optimize channel strategies by strengthening partnerships with hospital pharmacies for acute care settings, online pharmacies for chronic care continuity, and retail partners for community-level access and education. Develop differentiated lifecycle plans that include strategic sequencing of branded innovations and planned generic transitions, accompanied by targeted communication strategies for vulnerable age cohorts and gender-specific adherence interventions. Finally, embed sustainability and quality-by-design principles into operational planning to enhance long-term resilience and stakeholder trust.

Methodological framework combining primary stakeholder interviews, rigorous secondary evidence synthesis, and robust triangulation to ensure actionable intelligence and analytical rigor

The analysis underpinning this executive summary synthesizes multiple qualitative and quantitative research streams to ensure robust and actionable insights. Primary research included in-depth interviews with clinicians, payer representatives, pharmacy leaders, and industry executives to capture frontline perspectives on prescribing behavior, reimbursement drivers, and supply-chain constraints. Secondary research involved a systematic review of peer-reviewed clinical trials, regulatory filings, adjudicated outcomes studies, and guideline updates to verify therapeutic positioning and safety signals.

Data triangulation methods were applied to reconcile insights across sources, with particular emphasis on aligning clinical trial evidence with real-world utilization patterns observed in claims and electronic health record studies. Segmentation mapping incorporated drug class, route of administration, treatment line, distribution channel, brand type, and patient demographics to produce a multidimensional view of adoption dynamics. Quality assurance processes included expert validation sessions and methodological audits to ensure analytical rigor. Limitations are acknowledged where public data are sparse or where evolving regulatory decisions may alter therapeutic trajectories; nevertheless, the methodological framework provides a defensible basis for strategic planning and operational decision-making.

Integrated synthesis of clinical innovation, payer dynamics, and operational resilience to guide strategic decision-making across the diabetes therapy lifecycle

In aggregate, the type 2 diabetes landscape is characterized by accelerating clinical innovation, shifting payer expectations, and operational pressures that together demand integrated strategic responses. Therapies that demonstrate multi-system benefits-particularly those with favorable cardiovascular and renal profiles-are reshaping clinical paradigms, while delivery-mode innovation and digital support are redefining adherence and care continuity. At the same time, trade policy dynamics and supply-chain vulnerabilities require proactive sourcing and manufacturing strategies to maintain access and competitiveness.

Leaders who align evidence generation with pragmatic commercialization tactics, invest in resilient supply chains, and engage payers with outcomes-focused propositions will be best positioned to translate therapeutic advances into sustained patient benefit and organizational value. The insights in this executive summary are designed to inform cross-functional decision-making across clinical development, commercial strategy, supply chain, and policy engagement to navigate near-term disruptions and capture long-term opportunities in diabetes care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Type 2 Diabetes Drugs Market, by Drug Class

  • 8.1. Biguanides
    • 8.1.1. Combination Formulations
    • 8.1.2. Extended Release
    • 8.1.3. Immediate Release
  • 8.2. DPP-4 Inhibitors
    • 8.2.1. Alogliptin
    • 8.2.2. Linagliptin
    • 8.2.3. Saxagliptin
    • 8.2.4. Sitagliptin
  • 8.3. GLP-1 Receptor Agonists
    • 8.3.1. Dulaglutide
    • 8.3.2. Exenatide
    • 8.3.3. Liraglutide
    • 8.3.4. Semaglutide
  • 8.4. Insulin
    • 8.4.1. Basal
      • 8.4.1.1. Degludec
      • 8.4.1.2. Detemir
      • 8.4.1.3. Glargine
    • 8.4.2. Prandial
      • 8.4.2.1. Aspart
      • 8.4.2.2. Glulisine
      • 8.4.2.3. Lispro
    • 8.4.3. Premixed
      • 8.4.3.1. 50/50 Mix
      • 8.4.3.2. 70/30 Mix
      • 8.4.3.3. 75/25 Mix
  • 8.5. SGLT2 Inhibitors
    • 8.5.1. Canagliflozin
    • 8.5.2. Dapagliflozin
    • 8.5.3. Empagliflozin
    • 8.5.4. Ertugliflozin
  • 8.6. Sulfonylureas
    • 8.6.1. Chlorpropamide
    • 8.6.2. Glimepiride
    • 8.6.3. Glipizide
    • 8.6.4. Glyburide
  • 8.7. Thiazolidinediones
    • 8.7.1. Pioglitazone
    • 8.7.2. Rosiglitazone

9. Type 2 Diabetes Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Pen
    • 9.1.2. PreFilled Syringe
  • 9.2. Oral
    • 9.2.1. Capsule
    • 9.2.2. Tablet

10. Type 2 Diabetes Drugs Market, by Treatment Line

  • 10.1. First Line
    • 10.1.1. Combination
      • 10.1.1.1. Dual Therapy
      • 10.1.1.2. Triple Therapy
    • 10.1.2. Monotherapy
  • 10.2. Second Line
  • 10.3. Third Line

11. Type 2 Diabetes Drugs Market, by Brand Type

  • 11.1. Branded
  • 11.2. Generic

12. Type 2 Diabetes Drugs Market, by Patient Age Group

  • 12.1. 18 To 65
  • 12.2. Above 65

13. Type 2 Diabetes Drugs Market, by Patient Gender

  • 13.1. Female
  • 13.2. Male

14. Type 2 Diabetes Drugs Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Type 2 Diabetes Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Type 2 Diabetes Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Type 2 Diabetes Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Type 2 Diabetes Drugs Market

19. China Type 2 Diabetes Drugs Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Astellas Pharma Inc.
  • 20.6. AstraZeneca PLC
  • 20.7. Bayer AG
  • 20.8. Biocon Limited
  • 20.9. Boehringer Ingelheim International GmbH
  • 20.10. Bristol-Myers Squibb Company
  • 20.11. Chong Kun Dang Pharmaceutical Corp.
  • 20.12. Eli Lilly and Company
  • 20.13. Gilead Sciences, Inc.
  • 20.14. Hanmi Pharmaceutical Co., Ltd.
  • 20.15. Innovent Biologics Co., Ltd.
  • 20.16. Johnson & Johnson Services, Inc.
  • 20.17. Merck & Co., Inc.
  • 20.18. Novartis AG
  • 20.19. Novo Nordisk A/S
  • 20.20. Oramed Pharmaceuticals, Inc.
  • 20.21. Pfizer Inc.
  • 20.22. Sanofi S.A.
  • 20.23. Takeda Pharmaceutical Company Limited
  • 20.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DUAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DUAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TRIPLE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TRIPLE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 18 TO 65, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 18 TO 65, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 18 TO 65, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ABOVE 65, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ABOVE 65, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ABOVE 65, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. MIDDLE EAST TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD